Delving into the Latest Updates on Glutathione with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Glutathione (JP17), Glutathione (reduced type), Tathion

+ [1]

Target-

Mechanism-

Therapeutic Areas

Infectious DiseasesCardiovascular DiseasesDigestive System Disorders+ [6]

Active Indication

Drug intoxicationHeavy Metal PoisoningHypertension, Pregnancy-Induced+ [8]

Inactive Indication-

Originator Organization

Choseido Pharmaceutical Co., Ltd.

Active Organization

Choseido Pharmaceutical Co., Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

JP (30 Jun 1967),

ChorioretinitisCorneal UlcerHyperpigmentation+ [2]

Regulation-

Login to view timeline

Structure

Molecular FormulaC10H17N3O6S

InChIKeyRWSXRVCMGQZWBV-WDSKDSINSA-N

CAS Registry70-18-8

Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.

Start Date18 Jul 2024

Sponsor / Collaborator

George Washington University

CTRI/2024/04/066261 / Not yet recruitingPhase 1IIT

COMPARISON OF NANO SILVER FLUORIDE AND SDF WITH GLUTATHIONE TO EVALUATE CARIOSTATIC POTENTIAL AND DISCOLORATION IN PRIMARY TEETH-A RANDOMIZED CONTROL TRIAL - NIL

Start Date20 May 2024

Sponsor / Collaborator-

100 Clinical Results associated with Glutathione

Login to view more data

100 Translational Medicine associated with Glutathione

Login to view more data

100 Patents (Medical) associated with Glutathione

Login to view more data

2,579

Literatures (Medical) associated with Glutathione

01 Feb 2025·FOOD CHEMISTRY

Construction of a reaction-based fluorescent sensor for tandem detection of Cu2+ and glutathione in wine

Article

Author: Xu, Yan-Jun ; Yang, Han ; Li, Qing ; Yang, Feng ; Dai, Linjun ; Ren, Boquan ; Chen, Renqiang

The purpose of this study was to develop a novel reaction-based fluorescent sensor for the detection of Cu²⁺ and glutathione in real wine samples. The sensor, tris-(2-pyridyl)-methylamine rhodol derivative, was synthesized and validated for the tandem and selective detection of both Cu²⁺ and glutathione. The sensor exhibited a strong linear correlation between fluorescence intensity and Cu²⁺ concentration ranging from 100 to 900 nM, while the in situ generated Cu²⁺ ensemble selectively detected glutathione with a robust linear response from 3 to 30 μM. The detection limits for Cu²⁺ and glutathione were as low as 28 nM and 0.60 μM, respectively. Additionally, the sensor enabled quantitative detection of Cu²⁺ and glutathione in real wine samples. This work provides the first reaction-based fluorescence sensor with an "on-off-on" fluorescence response for the tandem detection of Cu²⁺ and glutathione in wine, offering potential applications in food and beverage quality control.

31 Dec 2024·Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology

Comparative effects of the antioxidant glutathione with metformin and Diane-35 on hormonal, metabolic, and inflammatory indicators in a DHEA-induced PCOS rat model

Article

Author: Tanoglu, Fatma Basak ; Tok, Olgu Enis ; Timur, Hikmet Tunç ; Özkara, Gülçin ; Coşar, Aslı ; Çetin, Çağlar ; Neccar, Duygu ; Özcan, Pınar

OBJECTIVE:

Comparison of hormonal, metabolic and inflammatory markers of glutathione with metformin and Diane-35 in a rat model of PCOS induced by dehydroepiandrosterone.

METHODS:

Twenty-five female rats were randomized into four groups. Group 1 was administered a subcutaneous dose of 0.2 ml saline/day. Group 2 was given 0.2 ml of 1% carboxymethyl cellulose (CMC)/day orally for 28 days. A PCOS model was established with DHEA in rats. Group 3 was given 4.5 mg/kg/day of Diane-35 orally dissolved in 1% CMC for 28 days. Group 4 was given 300 mg/kg/day of metformin orally dissolved in 1 ml of saline for 28 days, and Group 5 was administered 100 mg/kg of glutathione intraperitoneally on days 35, 42, and 49. On day 56, the rats were sacrificed. Serum markers and follicle count were examined.

RESULTS:

Serum IL-6, hs-CRP, insulin, testosterone, SHBG, and MDA values were significantly lower in the glutathione group than in the PCOS group (p = 0.0006, p = 0.023, p = 0.0082, p = 0.0007, p = 0.0048, and p < 0.0001, respectively).The number of all follicles was similar between the control and glutathione groups (p < 0.05). When we compared the other groups with the PCOS group, the number of primary, secondary, atretic, and cystic follicles was significantly lower in the metformin and glutathione groups. The number of primordial and antral follicles was significantly higher than in the PCOS group.

CONCLUSIONS:

Glutathione plays anti-inflammatory and antioxidant roles, similar to metformin, by lowering serum IL-6, insulin, testosterone, CRP, and MDA levels; decreasing atretic/cystic follicle count; and improving antral follicle count and folliculogenesis in PCOS patients.

31 Dec 2024·JOURNAL OF DERMATOLOGICAL TREATMENT

Noninvasive high-intensity focused ultrasound for skin brightening efficacy using a topical agent containing glutathione and hyaluronic acid

Article

Author: Lee, Angela Wai Kay ; Peng, Hsien Li Peter ; Lu, Sophie Pei-Hsuan ; Wan, Jovian ; Kim, Eunjae ; Huang, Po Han Patrick ; Yang, Yu-Chieh ; Huang, Jeff ; Yi, Kyu-Ho

BACKGROUND:

High-intensity focused ultrasound (HIFU) is well-documented for skin rejuvenation, lifting, and tightening. However, its synergistic effects with topical agents, enhanced by HIFU-induced vibration and heat, remain underexplored.

OBJECTIVE:

To evaluate clinical and photographic outcomes of HIFU combined with a topical agent versus the topical agent alone.

METHOD:

This non-randomized controlled trial involved 20 female volunteers (ages 30-55) divided into two groups. Group A (n = 10) received two HIFU sessions combined with a topical agent containing glutathione and hyaluronic acid. Group B (n = 10) received the topical agent alone. Outcomes were assessed using digital photography, patient satisfaction surveys, and the A-One Smart^™ system for fine wrinkles, hyperpigmentation, and hydration. Skin brightening was evaluated with the Global Esthetic Improvement Scale (GAIS).

RESULTS:

Group A showed significant reductions in fine wrinkles (6.25 ± 2.00 mm to 3.10 ± 1.62 mm), improved hyperpigmentation (3.50 ± 0.80 to 2.10 ± 1.05), and increased hydration (28 ± 10 to 55 ± 11) (all p < 0.05). Over two-thirds of Group A reported significant improvements, with no complications. Group B showed minimal, non-significant changes (p > 0.05), with only 30% reporting noticeable improvements.

CONCLUSION:

Combining HIFU with a topical agent significantly enhances skin quality and brightness without adverse effects.

100 Deals associated with Glutathione

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00014	-	V03AB32	DB00143

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Drug intoxication	JP	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Heavy Metal Poisoning	JP	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Hypertension, Pregnancy-Induced	JP	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Vomiting of pregnancy	JP	Choseido Pharmaceutical Co., Ltd.	22 Aug 1967
Chorioretinitis	JP	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Corneal Ulcer	JP	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Hyperpigmentation	JP	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Leukopenia	JP	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Stomatitis	JP	Choseido Pharmaceutical Co., Ltd.	30 Jun 1967
Liver Diseases	CN	-	-
Toxicity due to chemotherapy	CN	-	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02251041 (CAPITL, CTgov)	Phase 2	Reperfusion Injury	143	C1-Inhibitor+Epoprostenol+Infliximab+Melatonin+Alfa-tocopherol+Human recombinant erythropoietin+Glutathione	wprifcmtrv(bmrtdrtjqm) = shuidzchih ixvqmspimc (judthjpmri, oyzjpridhu - enrppqkmlo) View more	-	23 Aug 2024
NCT02311907 (CTgov)	Phase 3	Drug intoxication \| Alcoholic Neuropathy \| Ovarian Cancer ... View more	195	Carboplatin (A (Glutathione, Carboplatin))	hdqjsrkkbo(fwjdffihmi) = qlxutwssrp llhoovvzxv (kopurgoniu, vkyrutohen - vqiaoeogll) View more	-	23 Feb 2017
NCT02311907 (CTgov)	Phase 3		195	Placebo+Paclitaxel (B (Placebo, Paclitaxel))	hdqjsrkkbo(fwjdffihmi) = nnqzycjxjk llhoovvzxv (kopurgoniu, gsntcegtpl - jqmqzbfczy) View more	-	23 Feb 2017
ARVO2016	Not Applicable	Aphakia	-	glutathione	injarmebbm(icrrbgvubt) = lnxbcgmbsv ltnuybvktl (yhahtsqtja )	-	01 May 2016
ARVO2015	Not Applicable	-	-	Sodium nitroprusside (SNP)	ttswwmyczn(jzhsnmlrpl) = alkyjubsit voaovnkjlb (ghdfiqwchw ) View more	-	01 Jun 2015
NCT01450267 (ERS2012)	Phase 3	Cystic Fibrosis First line	94	Inhaled Glutathione	xxarffihdq(estlfljepr) = awcdlhgvbt wefuhgnjji (wftmamzhik )	Positive	01 Sep 2012
NCT01450267 (ERS2012)	Phase 3	Cystic Fibrosis First line	94	Placebo	xxarffihdq(estlfljepr) = yavlwycihx wefuhgnjji (wftmamzhik )	Positive	01 Sep 2012
ARVO2005	Not Applicable	stress oxidative	-	Glutathione	owbzeeplha(cvxfxlenum) = jetzsfgbyk gyvacliely (fktkcwzkhh )	-	01 May 2005